Henry Ford Health System and the Barbara Ann Karmanos Cancer Institute have launched a clinical research study to develop rapid and inexpensive blood test for the early diagnosis of pancreatic cancer.
The study will develop the test by identifying useful markers of cancer in the blood of high risk individuals and patients with high risk of pancreatic cancer.
For the study, Henry Ford will enroll 300 patients who are at high risk of pancreatic cancer and/or who have been diagnosed with pancreatic cancer.
The blood samples will undergo biomarker analysis at the Barbara Ann Karmanos Cancer Institute.